NZ727092A - Improved polyethyleneimine polyethyleneglycol vectors - Google Patents

Improved polyethyleneimine polyethyleneglycol vectors Download PDF

Info

Publication number
NZ727092A
NZ727092A NZ727092A NZ72709215A NZ727092A NZ 727092 A NZ727092 A NZ 727092A NZ 727092 A NZ727092 A NZ 727092A NZ 72709215 A NZ72709215 A NZ 72709215A NZ 727092 A NZ727092 A NZ 727092A
Authority
NZ
New Zealand
Prior art keywords
polyplex
cancer
peg
lpei
targeting moiety
Prior art date
Application number
NZ727092A
Other languages
English (en)
Inventor
Alex Levitzki
Salim Joubran
Alexei Shir
Maya Zigler
Alaa Talhami
Yael Langut
Original Assignee
Targimmune Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targimmune Therapeutics Ag filed Critical Targimmune Therapeutics Ag
Priority to NZ764423A priority Critical patent/NZ764423B2/en
Publication of NZ727092A publication Critical patent/NZ727092A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ727092A 2014-05-14 2015-05-14 Improved polyethyleneimine polyethyleneglycol vectors NZ727092A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ764423A NZ764423B2 (en) 2014-05-14 2015-05-14 Improved polyethyleneimine polyethyleneglycol vectors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461993110P 2014-05-14 2014-05-14
PCT/IL2015/050514 WO2015173824A1 (en) 2014-05-14 2015-05-14 Improved polyethyleneimine polyethyleneglycol vectors

Publications (1)

Publication Number Publication Date
NZ727092A true NZ727092A (en) 2021-07-30

Family

ID=54479412

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ727092A NZ727092A (en) 2014-05-14 2015-05-14 Improved polyethyleneimine polyethyleneglycol vectors

Country Status (16)

Country Link
US (4) US10278991B2 (https=)
EP (1) EP3142673A4 (https=)
JP (3) JP6753843B2 (https=)
KR (2) KR102589295B1 (https=)
CN (3) CN116966310A (https=)
AU (2) AU2015260725B2 (https=)
CA (1) CA2949017A1 (https=)
IL (2) IL287206B2 (https=)
MA (1) MA39970A (https=)
MX (2) MX377654B (https=)
NZ (1) NZ727092A (https=)
PH (1) PH12016502258B1 (https=)
RU (1) RU2771104C2 (https=)
SG (2) SG10201911695SA (https=)
WO (1) WO2015173824A1 (https=)
ZA (1) ZA201608042B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102589295B1 (ko) * 2014-05-14 2023-10-13 타르그이뮨 테라퓨틱스 아게 개선된 폴리에틸렌이민 폴리에틸렌글리콜 벡터
EP3319587B1 (en) * 2015-11-17 2019-08-21 Bioncotech Therapeutics, S.L Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
JP6937773B2 (ja) * 2016-03-07 2021-09-22 ハンミ ファーマシューティカル カンパニー リミテッド ポリエチレングリコール誘導体及びその用途
JP7096249B2 (ja) 2016-09-04 2022-07-05 ターグイミューン セラピューティクス アーゲー ｄｓＲＮＡを標的化するためのキメラタンパク質
US10849921B2 (en) 2017-05-17 2020-12-01 Bioncotech Therapeutics Sl Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
IL273195B2 (en) * 2017-09-27 2024-04-01 Targimmune Therapeutics Ag Castration-resistant prostate cancer
EP3762417A1 (en) * 2018-03-08 2021-01-13 TargImmune Therapeutics AG A recombinant protein comprising a double stranded rna binding domain
CN109893657B (zh) * 2019-02-28 2022-04-29 中国人民解放军军事科学院军事医学研究院 基因递送载体、药物复合物、抗肺纤维化药物及应用
KR20210146952A (ko) * 2019-04-03 2021-12-06 타르그이뮨 테라퓨틱스 아게 암의 치료를 위한 면역요법
WO2020263782A1 (en) * 2019-06-24 2020-12-30 North Carolina State University Methods and compositions for modifying nucleic acids and for killing cells
WO2021001023A1 (en) * 2019-07-02 2021-01-07 Biontech Rna Pharmaceuticals Gmbh Rna formulations suitable for therapy
KR20230084476A (ko) 2020-10-08 2023-06-13 타르그이뮨 테라퓨틱스 아게 암의 치료를 위한 면역요법
WO2023079142A2 (en) 2021-11-05 2023-05-11 Targimmune Therapeutics Ag Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
US20240091348A1 (en) * 2022-09-20 2024-03-21 Highlight Therapeutics, S.L. Novel compositions based on polyinosinic-polycytidylic acid
IL320615A (en) 2022-11-07 2025-07-01 Targimmune Therapeutics Ag PSMA-targeting linear conjugates containing polyethyleneimine and polyethylene glycol and polyplexes containing the same materials
IL320618A (en) 2022-11-07 2025-07-01 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted pairs containing polyethyleneimine and polyethylene glycol
US20260000700A1 (en) * 2022-11-07 2026-01-01 Targimmune Therapeutics Ag Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
WO2025238236A1 (en) 2024-05-16 2025-11-20 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0532525B1 (de) 1990-05-18 1995-08-16 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Neue protein-polykation-konjugate
DE4104186A1 (de) 1991-02-12 1992-08-13 Genentech Inc Neue, ueber endozytose in hoehere eukaryotische zellen aufnehmbare, nukleinsaeure enthaltende komplexe
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
DE19726186A1 (de) 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
DE69942581D1 (de) 1998-05-25 2010-08-26 Nippon Shinyaku Co Ltd Verfahren zur herstellung einer nucleinsäure enthaltenden kompositzusammenstellung
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
US20040043030A1 (en) 2001-07-31 2004-03-04 Immunomedics, Inc. Polymeric delivery systems
GB0119346D0 (en) 2001-08-08 2001-10-03 Bioclones Proprietary Ltd Process for the maturation of dendritic cells
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
KR20030043780A (ko) 2001-11-28 2003-06-02 주식회사 바이오폴리메드 생체적합성 비항원성 공중합체와 그 결합체 및 이들의제조방법
AU2002236324A1 (en) 2002-02-28 2003-09-09 Jong Sang Park Cationic highly branched polyaminoester
AU2003258100A1 (en) 2002-08-06 2004-02-23 Intradigm Corporation Methods of down regulating target gene expression in vivo by introduction of interfering rna
US7927792B2 (en) 2002-11-18 2011-04-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Targeted double stranded RNA mediated cell killing
US8324365B2 (en) 2003-04-03 2012-12-04 Korea Advanced Institute Of Science And Technology Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof
US8969543B2 (en) 2003-04-03 2015-03-03 Bioneer Corporation SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20050118718A1 (en) 2003-09-22 2005-06-02 University Of Utah Research Foundation Stabilization and controlled delivery of ionic biopharmaceuticals
US20050277575A1 (en) 2004-03-24 2005-12-15 Alexandre Semov Therapeutic compositions and methods for treating diseases that involve angiogenesis
CA2587676A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US7893244B2 (en) 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
CN101287500A (zh) * 2005-08-19 2008-10-15 恩多塞特公司 多药物配体缀合物
WO2007133812A2 (en) 2005-12-30 2007-11-22 Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine Improved carriers for delivery of nucleic acid agents to cells and tissues
WO2007084797A1 (en) 2006-01-23 2007-07-26 Abbott Laboratories Chemically modified polycation polymer for sirna delivery
US20070225213A1 (en) 2006-03-23 2007-09-27 Kosak Matthew K Nucleic acid carriers for delivery of therapeutic agents
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
EP2436376B1 (en) 2007-09-28 2014-07-09 BIND Therapeutics, Inc. Cancer cell targeting using nanoparticles
JP2011500569A (ja) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
WO2009110939A2 (en) 2007-12-10 2009-09-11 Massachusetts Institute Of Technology Drug delivery system for pharmaceuticals and radiation
EP2247308A4 (en) 2008-01-10 2012-04-18 Nventa Biopharmaceuticals Corp AUXILIARY COMPOSITIONS WITH POLY-IC AND A CATIONIC POLYMER
WO2009131435A1 (en) 2008-04-23 2009-10-29 Erasmus University Medical Center Rotterdam Linker containing bungarotoxin and a binding peptide
EP2113257A1 (en) 2008-04-30 2009-11-04 Consorzio per il Centro di Biomedica Moleculare Scrl Polyelectrolyte with positive net charge for use as medicament and diagnostic for cancer
EP2123304A1 (en) 2008-05-23 2009-11-25 Freie Universität Berlin Compounds suited as nanocarriers for active agents and their use
WO2009151539A1 (en) 2008-05-24 2009-12-17 Sirnaomics, Inc. COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS
JP2011525180A (ja) 2008-06-16 2011-09-15 バインド バイオサイエンシズ インコーポレイテッド 治療的標的化ナノ粒子の製作に用いるためのジブロックコポリマーで官能化された標的薬の製造方法
US9006406B2 (en) * 2008-12-22 2015-04-14 Alexander Levitzki EGFR-homing double-stranded RNA vector for systemic cancer treatment
WO2010088927A1 (en) 2009-02-09 2010-08-12 Curevac Gmbh Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
US20100266642A1 (en) 2009-02-20 2010-10-21 Bind Biosciences, Inc. Modified cells for targeted cell trafficking and uses thereof
WO2010114169A1 (en) 2009-03-31 2010-10-07 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
US8287910B2 (en) 2009-04-30 2012-10-16 Intezyne Technologies, Inc. Polymeric micelles for polynucleotide encapsulation
ES2368963B1 (es) 2009-07-04 2012-10-10 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Procedimiento de identificación de agentes terapéuticos contra el melanoma y uso de agente identificado.
CN101638484A (zh) * 2009-08-24 2010-02-03 中国科学院长春应用化学研究所 聚乙二醇单甲醚-聚2-甲基-2-羧基碳酸丙烯酯接枝聚乙烯亚胺共聚物与制法及应用
AU2010328136B2 (en) 2009-12-09 2016-02-25 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
WO2011084521A2 (en) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same
EP2515942B1 (en) 2009-12-15 2020-02-12 Pfizer Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
EA201290497A1 (ru) 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых
SI2539451T1 (sl) 2010-02-24 2016-04-29 Arrowhead Research Corporation Sestavki za ciljano dostavo sirna
EP2542678B1 (en) 2010-03-04 2017-04-12 InteRNA Technologies B.V. A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS THERAPEUTIC USES IN CANCER ASSOCIATED WITH EMT
WO2011130577A1 (en) 2010-04-14 2011-10-20 Intezyne Technologies, Incorporated Controlled polyplex assembly
EP2395041A1 (en) 2010-06-10 2011-12-14 F. Hoffmann-La Roche AG Polymers for delivery of nucleic acids
WO2011154331A1 (en) 2010-06-10 2011-12-15 F. Hoffmann-La Roche Ag Polymers for delivery of nucleic acids
EP2591106A1 (en) 2010-07-06 2013-05-15 InteRNA Technologies B.V. Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
US20120207795A1 (en) 2010-07-13 2012-08-16 The Regents Of The University Of California Cationic polymer coated mesoporous silica nanoparticles and uses thereof
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
FR2963350B1 (fr) 2010-07-30 2013-11-01 Univ D Evry Val D Essonne Nouveaux copolymeres a bloc et leurs utilisations pour delivrer une substance active dans une cellule.
US8461224B2 (en) 2011-03-04 2013-06-11 National Health Research Institutes Single monomer derived linear-like copolymer comprising polyethylenimine and poly(ethylene glycol) for nucleic acid delivery
EP2691120A4 (en) 2011-03-31 2014-09-24 Univ Johns Hopkins THEROSTATIC ILLUSTRATION AND USE METHOD THEREFOR
US20140308363A1 (en) 2011-05-31 2014-10-16 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
EA201492004A1 (ru) 2012-05-02 2015-08-31 Новартис Аг Органические композиции для лечения kras-ассоциированных заболеваний
RS54944B1 (sr) 2012-07-12 2016-11-30 Proqr Therapeutics Ii Bv Oligonukleotidi za pravljenje promena u sekvencama ciljanih rnk molekula prisutnih u živoj ćeliji
JP2015536319A (ja) 2012-10-16 2015-12-21 ウィリアム・マーシュ・ライス・ユニバーシティ 薬剤耐性を克服するための改善されたナノベクターベースの薬物送達システム
EP2917348A1 (en) 2012-11-06 2015-09-16 InteRNA Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
EA201590783A1 (ru) 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
JP6446269B2 (ja) 2012-12-06 2018-12-26 協和発酵バイオ株式会社 アジュバント用二重鎖リボ核酸
US12064484B2 (en) 2013-06-28 2024-08-20 Ethris Gmbh Compositions for introducing RNA into cells
CN104341488A (zh) 2013-08-02 2015-02-11 复旦大学 c(LyP-1)多肽及其构建的纳米递药系统和应用
US20160312218A1 (en) 2013-11-04 2016-10-27 Northeastern University System for co-delivery of polynucleotides and drugs into protease-expressing cells
WO2015070080A2 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Nucleic acid nanostructures for in vivo agent delivery
PE20170312A1 (es) 2014-03-14 2017-03-30 Pfizer Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso
EP3126501A1 (en) 2014-03-24 2017-02-08 RiboxX GmbH Double-stranded rna conjugates and their use
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
KR102589295B1 (ko) 2014-05-14 2023-10-13 타르그이뮨 테라퓨틱스 아게 개선된 폴리에틸렌이민 폴리에틸렌글리콜 벡터
EP3253414A4 (en) 2015-02-05 2018-07-11 The University Of Queensland Targeting constructs for delivery of payloads
US20160331845A1 (en) 2015-05-14 2016-11-17 The Johns Hopkins University Compositions of nucleic acid-containing nanoparticles for in vivo delivery
EP3319587B1 (en) 2015-11-17 2019-08-21 Bioncotech Therapeutics, S.L Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine

Also Published As

Publication number Publication date
CN116966311A (zh) 2023-10-31
JP7406475B2 (ja) 2023-12-27
IL287206B1 (en) 2023-10-01
JP2017521090A (ja) 2017-08-03
RU2016146389A (ru) 2018-06-15
CN116966310A (zh) 2023-10-31
ZA201608042B (en) 2018-11-28
JP2020196739A (ja) 2020-12-10
MA39970A (fr) 2015-11-19
US11298376B2 (en) 2022-04-12
AU2021203336A1 (en) 2021-06-24
MX2016014881A (es) 2017-05-01
US10543232B2 (en) 2020-01-28
RU2016146389A3 (https=) 2018-12-26
KR102589295B1 (ko) 2023-10-13
AU2015260725A1 (en) 2016-12-22
AU2015260725B2 (en) 2021-02-25
CN106687121A (zh) 2017-05-17
WO2015173824A1 (en) 2015-11-19
US20170072063A1 (en) 2017-03-16
US20190262395A1 (en) 2019-08-29
US20220339189A1 (en) 2022-10-27
KR20220163536A (ko) 2022-12-09
RU2771104C2 (ru) 2022-04-26
IL287206A (en) 2021-12-01
BR112016026581A2 (pt) 2017-10-31
MX377654B (es) 2025-03-11
IL287206B2 (en) 2024-02-01
SG10201911695SA (en) 2020-01-30
MX2020012698A (es) 2021-02-15
EP3142673A4 (en) 2018-01-03
IL248890A0 (en) 2017-01-31
AU2021203336B2 (en) 2024-11-07
KR102472590B1 (ko) 2022-11-30
SG11201609442YA (en) 2016-12-29
US20190192563A1 (en) 2019-06-27
EP3142673A1 (en) 2017-03-22
US10278991B2 (en) 2019-05-07
IL248890B (en) 2021-10-31
PH12016502258B1 (en) 2022-08-03
KR20170005052A (ko) 2017-01-11
NZ764423A (en) 2021-08-27
PH12016502258A1 (en) 2017-02-27
CA2949017A1 (en) 2015-11-19
JP2024028995A (ja) 2024-03-05
AU2021203336C1 (en) 2025-05-08
JP6753843B2 (ja) 2020-09-16

Similar Documents

Publication Publication Date Title
AU2021203336B2 (en) Improved polyethyleneimine polyethyleneglycol vectors
US8697667B2 (en) Cyclodextrin-modified polyamines for delivery of therapeutic molecules
WO2023079142A2 (en) Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
Yu et al. Improved method for synthesis of low molecular weight protamine–siRNA conjugate
Luo et al. Artificial peptides for antitumoral siRNA delivery
WO2008070141A2 (en) Compositions for delivery of therapeutic agents
JP2025537216A (ja) 核酸とポリエチレンイミンおよびポリエチレングリコールを含む標的化コンジュゲートとのポリプレックス
NZ764423B2 (en) Improved polyethyleneimine polyethyleneglycol vectors
WO2024190929A1 (ja) タンパク質送達用ｐＨ応答性担体
EP2388016A1 (en) Non-viral nucleic acid molecules delivery systems
BR112016026581B1 (pt) Poliplexo de um rna de fita dupla (dsrna) e um conjugado polimérico, uso do poliplexo e composições farmacêuticas que o compreendem
WO2025238236A1 (en) Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol
EP4426358A2 (en) Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
WO2023247781A1 (en) Peptides for intracellular delivery
Hamilton Advanced drug delivery systems from tailored building blocks: Controlled intracellular delivery of bioactive cargo

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: TARGIMMUNE THERAPEUTICS AG, CH

Effective date: 20170706

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAY 2023 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20220502

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAY 2024 BY DENNEMEYER + CO

Effective date: 20230501

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAY 2025 BY DENNEMEYER + CO.

Effective date: 20240506

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAY 2026 BY DENNEMEYER AND CO. SARL

Effective date: 20250505